Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110264 · ClinicalTrials.gov registry record · Phase 3
Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
A Phase 3 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 3
- Development phase
- 151
- Enrollment target
NCT02110264 is a Phase 3 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 151 participants.
The verdict
NCT02110264, a Phase 3 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 151 participants
- Enrollment target
Study Summary
The aim of this trial is to assess the clinical utility, effectiveness, and cost implications of treatment for incarcerated offenders with opioid use disorders who are randomly assigned to one of three treatment conditions to include a depot formulation of naltrexone (XR-NTX, as Vivitrol®) only (XR-NTX), Vivitrol provided with sessions with a patient navigator (PN) XR-NTX+PN, and a drug education procedure (ETAU) before being released to the community. This trial will investigate whether effective medication therapy used in non-incarcerated populations will also be effective in incarcerated individuals. Empirical evidence demonstrates that starting treatment before release greatly increases the probability of successful outcome including reduced alcohol and drug use, increased employment rates, and reduced recidivism rates.
Interventions
- BEHAVIORAL ETAU
- DRUG XR-NTX
- BEHAVIORAL XR-NTX+PN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2015-06 |
| Est. Completion | 2019-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02110264
The ClinicalTrials.gov registry entry for NCT02110264 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ETAU is the first listed.
NCT02110264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02110264 about?
NCT02110264 is a clinical study titled "Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)". The aim of this trial is to assess the clinical utility, effectiveness, and cost implications of treatment for incarcerated offenders with opioid use disorders who are randomly assigned to one of three treatment conditions to include a depot formulation of naltrexone (XR-NTX, as Vivitrol®) only (XR-...
What is the current status of trial NCT02110264?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 151 participants. The study started on 2015-06. Estimated completion is 2019-05.
What interventions are being tested in trial NCT02110264?
The interventions under investigation include: ETAU (BEHAVIORAL), XR-NTX (DRUG), XR-NTX+PN (BEHAVIORAL).
Who is sponsoring clinical trial NCT02110264?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.